Breaking Finance News

A statement released earlier today by finnCap about Avacta Group PLC (LON:AVCT) maintains the target price at 200.00GBX

Avacta Group PLC (LON:AVCT) had its target price hold steady to 200.00GBX by finnCap in a report released 11/23/2016. The new target price indicates a possible upside of 1.26% based on the company's previous stock price.

Just yesterday Avacta Group PLC (LON:AVCT) traded 0.00% even at 88.50GBX. Avacta Group PLC’s 50-day moving average is 90.23GBX and its 200-day moving average is 96.22GBX. The last stock price is down -8.02% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 500 shares of AVCT traded hands, down from an average trading volume of 12,654

Recent Performance Chart

Avacta Group PLC (LON:AVCT)

Avacta Group PLC has 52 week low of 83.02GBX and a 52 week high of 134.50GBX and has a market capitalization of 0 GBX.

In addition to finnCap reporting its stock price target, a total of 1 brokerage has issued a ratings update on the company. The average stock price target is 160.00GBX with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Avacta Group PLC (LON:AVCT)

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company's segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company's in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.